Squarepoint
ABBV icon

Squarepoint’s AbbVie ABBV Stock Holding History

Squarepoint’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.94M Sell
45,700
-35,800
-44% -$7.94M 0.01% 1071
2025
Q4 		$18.6M Sell
81,500
-4,600
-5% -$1.05M 0.02% 772
2025
Q3 		$19.9M Sell
86,100
-117,500
-58% -$23.9M 0.02% 748
2025
Q2 		$37.8M Sell
203,600
-23,900
-11% -$4.44M 0.04% 486
2025
Q1 		$47.7M Buy
227,500
+75,600
+50% +$14.7M 0.06% 362
2024
Q4 		$27M Buy
151,900
+31,900
+27% +$5.87M 0.03% 618
2024
Q3 		$23.7M Buy
120,000
+24,400
+26% +$4.55M 0.04% 520
2024
Q2 		$16.4M Sell
95,600
-177,400
-65% -$29.4M 0.03% 684
2024
Q1 		$49.7M Buy
273,000
+263,600
+2,804% +$45.4M 0.09% 261
2023
Q4 		$1.46M Sell
9,400
-15,400
-62% -$2.25M ﹤0.01% 2246
2023
Q3 		$3.7M Hold
24,800
– – 0.01% 1374
2023
Q2 		$3.34M Buy
24,800
+23,400
+1,671% +$3.43M 0.01% 1324
2023
Q1 		$223K Sell
1,400
-39,300
-97% -$6.01M ﹤0.01% 2743
2022
Q4 		$6.58M Buy
40,700
+32,200
+379% +$4.94M 0.03% 691
2022
Q3 		$1.14M Sell
8,500
-8,900
-51% -$1.28M 0.01% 1674
2022
Q2 		$2.67M Sell
17,400
-55,300
-76% -$8.45M 0.01% 1018
2022
Q1 		$11.8M Sell
72,700
-23,200
-24% -$3.37M 0.05% 397
2021
Q4 		$13M Sell
95,900
-2,100
-2% -$248K 0.03% 439
2021
Q3 		$10.6M Buy
98,000
+300
+0.3% +$34.3K 0.03% 480
2021
Q2 		$11M Sell
97,700
-38,300
-28% -$4.31M 0.04% 436
2021
Q1 		$14.7M Sell
136,000
-25,000
-16% -$2.67M 0.09% 264
2020
Q4 		$17.3M Buy
161,000
+158,500
+6,340% +$15.2M 0.13% 144
2020
Q3 		$219K Buy
2,500
+200
+9% +$18.8K ﹤0.01% 2029
2020
Q2 		$226K Buy
+2,300
New +$203K ﹤0.01% 1765
2020
Q1 		– Sell
-2,800
Closed -$248K – 1794
2019
Q4 		$248K Sell
2,800
-12,800
-82% -$1.06M ﹤0.01% 2128
2019
Q3 		$1.18M Buy
15,600
+11,300
+263% +$775K 0.01% 1112
2019
Q2 		$313K Buy
4,300
+200
+5% +$15.7K ﹤0.01% 1917
2019
Q1 		$330K Buy
+4,100
New +$335K ﹤0.01% 1723

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's ABBV Position: Q1 2026 in Review

Squarepoint increased its AbbVie (ABBV) stake by 160% in Q1 2026, buying an estimated $26.5M and bringing the position to 193,871 shares worth $42.2M. The position accounts for 0.05% of the portfolio, ranked #384.

Squarepoint first reported a position in ABBV in Q3 2015 and has held it in 31 quarters since. The position peaked at $92.1M in Q2 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Squarepoint held 193,871 shares of AbbVie worth $42.2M as of Q1 2026.
  • Squarepoint bought 119,297 AbbVie shares in Q1 2026, an estimated $26.5M.
  • AbbVie made up 0.05% of Squarepoint's portfolio in Q1 2026, its #384 holding.
  • Squarepoint first reported a position in AbbVie in Q3 2015 and has held it in 31 quarters since.
  • Squarepoint's AbbVie position peaked at $92.1M in Q2 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.